Latest Biotechnology News

Page 50 of 80
Nyrada Inc. has raised $8.25 million through a strategic placement to fund its upcoming Phase IIa clinical trial of Xolatryp for acute myocardial infarction, positioning the company for a pivotal year ahead.
Ada Torres
Ada Torres
4 Aug 2025
Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy to dose level 2 in its Phase 1/2 trial, showing promising early anti-tumor activity and a strong safety profile in gastrointestinal and neuroendocrine cancers.
Ada Torres
Ada Torres
4 Aug 2025
Syntara Limited reported a $3.7 million cash outflow from operations in the June quarter but bolstered its balance sheet with an $18.5 million capital raise, ending the period with $15.1 million in cash.
Ada Torres
Ada Torres
1 Aug 2025
BPH Global has transitioned from development to early commercial sales in its Indonesian seaweed operations, securing key offtake agreements and advancing multiple R&D projects. The company also raised $609,000 in fresh capital, positioning itself for growth in sustainable biotech markets.
Ada Torres
Ada Torres
31 July 2025
Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.
Ada Torres
Ada Torres
31 July 2025
Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.
Ada Torres
Ada Torres
31 July 2025
Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.
Ada Torres
Ada Torres
31 July 2025
Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.
Ada Torres
Ada Torres
31 July 2025
Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.
Ada Torres
Ada Torres
31 July 2025
Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.
Ada Torres
Ada Torres
31 July 2025
Hexima Limited reported a stable cash balance of AUD 1.54 million for Q2 2025, with only minor net cash used in operating activities. The company remains focused on strategic opportunities to enhance shareholder value.
Ada Torres
Ada Torres
31 July 2025
Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.
Ada Torres
Ada Torres
31 July 2025